This randomized, double-blind, double-dummy, multicentre cross-over study compared the eects on the hypothalamic-pituitary-adrenal (HPA) axis of¯uticasone propionate (750 mg twice daily given via the Diskus TM and budesonide (800 mg twice daily given via the Turbuhaler TM . Two treatment periods of 2 weeks each were preceded by a 2-week run-in period and separated by a 2-week washout period. During run-in and washout, patients received beclomethasone dipropionate (BDP) or budesonide at a constant dose of 1500±1600 mg day
Introduction
Inhaled corticosteroids are now well established in the treatment of asthma, and are considered to have an essential role in the management of most asthmatic patients (1) . Guidelines on asthma management published in Europe and the U.S.A. recommend the use of inhaled corticosteroids as ®rst-line therapy in all but the mildest cases of asthma (2, 3) .
Although inhaled corticosteroids have a far lower potential for systemic eects than oral corticosteroid therapy, this potential is not zero and the systemic eects of long-term inhaled corticosteroid therapy have been much studied in recent years (for a review, see reference 1). Longterm therapy at high doses may sometimes produce clinically evident systemic eects, such as skin thinning or easy bruising (4, 5) . Other potential systemic eects include suppression of the hypothalamic-pituitary-adrenal (HPA) axis, reduced bone density and growth impairment in children (6) . Of these, HPA suppression is the most sensitive and easily measured marker of the systemic activity of inhaled corticosteroids (1) .
Systemic exposure to inhaled corticosteroids occurs via two routes. Part of an inhaled dose is deposited in the lower airways and absorbed into the pulmonary circulation. The remainder, which may be up to 80% (7) , is deposited in the mouth and on the back of the throat. Unless rinsed out, it will eventually be swallowed and absorbed through the gut. Some may be inactivated by ®rst-pass metabolism in the liver, and the rest will reach the systemic circulation.
At the doses required by most adult asthmatics, up to approximately 800 mg day 71 of beclomethasone dipropionate (BDP) or budesonide (BUB), inhaled corticosteroids have an excellent safety pro®le (8) . However, in adults with moderate to severe asthma, doses of up to 2000 mg day 71 of BDP may be required to achieve satisfactory disease control (3) . Signi®cant HPA axis suppression has been observed in adults receiving BDP at doses in excess of 1000 mg day 71 (9) or 1500 mg day 71 (6) . Therefore, there is a need for an inhaled corticosteroid with high potency but low potential for systemic eects, even at high doses.
Fluticasone propionate (FP) has the highest receptor anity of the inhaled corticosteroids in clinical use (10±12) and has been shown to be more potent than either BDP or BUD in a variety of in vitro models (13±17). These results are supported by clinical studies, which consistently report that FP is at least as ecacious as twice the microgram dose of either BDP (18, 19) or BUD (20±23), across a dose range of FP from 200 to 800 mg day 71 . At doses of up to 2000 mg day 71 in patients with severe asthma, FP is more eective than an equal dose of BDP (24) or BUD (25) . Moreover FP has negligible oral bioavailability, as it is subjected to near-complete ®rst-pass metabolism in the liver (26, 27) . This eectively eliminates the oral route for systemic absorption.
In patients with severe asthma, 1500 mg day 71 FP produces no more HPA suppression than an equal dose of BDP (24) . A higher FP dose (2000 mg day 71 ) produces a greater suppression of serum cortisol than 1600 mg day 71 BUD, but values still remain within the normal range (25) . However, a study in healthy adult volunteers has reported that FD produces greater suppression of the HPA axis than BUD over the dose range of 400±2000 mg day 71 administered by metered-dose inhaler (28) .
In the above-mentioned studies, the inhalation devices used were metered dose inhalers (MDIs) or Diskhaler. Nowadays, the dry-powder devices Diskus TM (Glaxo Wellcome, London, U.K.) and Turbuhaler TM (Astrazeneca, Lund, Sweden) are most frequently used, at least in Scandinavia (36). The present study was carried out to compare the HPA-suppressing eects of FP (1500 mg day
71
) and BUD (1600 mg day 71 ) given via dry-powder inhalation devices (Diskus  TM and Turbuhaler   TM , respectively) as a primary objective in adult patients with moderate to severe asthma who require these speci®c high doses of steroid treatment.
Methods

STUDY DESIGN
The study was a randomized, double-blind, double-dummy, cross-over study (Fig. 1) . Two treatment periods of 2 weeks each were separated by a 2-week washout period and preceded by a 2-week run-in. Study visits took place prior to run-in, after the run-in period (baseline 1), after the ®rst treatment period, after the washout period (baseline 2) and after the second treatment period.
During the run-in and washout periods, patients received their usual medication for reversible obstructive airways disease, which could include inhaled corticosteroids (BDP or BUD), oral xanthine derivatives, sodium cromoglycate, long-acting b 2 -agonists, anti-histamines, inhaled anti-cholinergics and oral b 2 -agonists. All medication doses were held constant throughout the study. The same inhaled corticosteroid was used during the run-in and washout periods. Compliance was checked by counting doses left over on the Diskus TM . During the two treatment periods, the patients' usual inhaled corticosteroid was replaced by study medication. This was either FD 750 mg twice daily via the Diskus TM dry powder inhaler or BUD 800 mg twice daily via the Turbuhaler TM , each with a matching placebo to maintain study blinding. Patients were randomized to receive either FD or BUD for the ®rst treatment period, and then switched to the other for the second treatment period. Short-acting b 2 -agonists, salbutamol or terbutaline, were permitted as rescue medication throughout the study.
The study was conducted in accordance with the Declaration of Helsinki (Hong Kong Amendment 1989), and was approved by the regional Ethical Committee in each country. All patients gave written informed consent for study participation.
PATIENTS
Patients were aged 18 to 75 years, with a clinical history of reversible obstructive airways disease responding to inhaled corticosteroids. All patients had been receiving inhaled corticosteroids for at least the last 3 months, and BUD (1600 mg day 71 ) or BDP (1500±1600 mg day
71
) at a constant dose for 4 weeks prior to randomization at Visit 1.
They were required to demonstrate correct use of the Diskus TM and Turbuhaler TM devices and a peak¯ow meter. Forced expiratory volume in 1 sec (FEV 1 ) was measured at Visits 1 and 2 and was required to be 50% or more of the predicted value on each occasion. All patients had to show a clear response to bronchodilator therapy. This was de®ned by comparing the peak expiratory¯ow (PEF) value obtained before inhaling any bronchodilator with the PEF obtained after inhalation of salbutamol. The mean morning PEF obtained before taking any medication on each of the last 7 days of the run-in period could be no more than 90% of the PEF obtained after inhalation of 400±800 mg salbutamol at Visit 2. Patients must also have experienced asthma symptoms (total diary card score of at least two per 24 h), or have used a short-acting b 2 -agonist on at least two occasions per 24 h, on at least 4 days during the run-in period. These selection criteria de®ned a patient group with moderate to severe symptomatic reversible obstructive airways disease.
Patients were excluded from the study for the following reasons: very poorly controlled asthma or chronic obstructive pulmonary disease; use of oral, parenteral or depot corticosteroids in the 4 weeks preceding Visit 1; pregnancy (or likelihood of becoming pregnant) or lactation in women; evidence of alcohol or drug abuse; known or suspected hypersensitivity to inhaled steroids; respiratory tract infection or hospitalization for respiratory disease in the 4 weeks prior to Visit 1; night shift work; evidence of serious uncontrolled systemic, psychological or other disease likely to interfere with the conduct of the study.
ASSESSMENTS
The primary ecacy variables were morning serum cortisol measured over the period from 08Á00 to 10Á30 hours for calculation of area under the curve (AUC), and 12-h nocturnal urinary cortisol excretion. Both these assessments are recognized measures of HPA axis function, and 12-h nocturnal urine cortisol excretion is regarded as the more sensitive of the two (1). Serum samples were taken at 08Á00, 08Á30, 09Á00, 09Á30, 10Á00 and 10Á30 hours at Visits 2, 3, 4 and 5, and urine was collected from 20Á00 to 08Á00 hours on the nights prior to Visits 2, 3, 4 and 5. Cortisol concentrations in serum and urine samples were determined by a central laboratory (CALAB, Sweden).
FEV 1 was measured at each visit using a spirometer and the highest of three measurements recorded. PEF was measured by the patients each morning (between 07Á00 and 09Á00 hours) and evening (between 19Á00 and 21Á00 hours) using a peak¯ow meter, and the highest of three measurements recorded on a diary card. Daytime asthma symptoms were assessed by the patients and recorded on a diary card, using a six-point scale (0no symptoms, 1symptoms for one short period, 2symptoms for two short periods, 3symptoms for most of the day but not interfering with normal activities, 4symptoms for most of the day which interfered with normal activities, 5symptoms for most of the day which prevented performance of normal activities). Nocturnal asthma symptoms were assessed and recorded in a similar manner, using a slightly dierent scale (0no symptoms, 1symptoms causing the patient to wake once or wake early, 2symptoms causing the patient to wake twice or more, 3symptoms keeping the patient awake most of the night, 4symptoms preventing the patient from sleeping at all). These measurements were used only in the run-in period to determine patients' eligibility for the trial and were not formally analysed.
STATISTICAL ANALYSIS
Forty patients would enable a treatment ratio of less than 0Á80 and greater than 1Á25 to be detected with 90% power at the 5% signi®cance level. Approximately 60 patients were to be recruited, with the aim of obtaining 40 evaluable patients at the end of the study.
Previously performed cross-over studies showed that a washout period of 2 weeks should be sucient for cortisol suppresion to recover (28, 37, 38) . In these studies, the washout period lasted from 3 to 14 days. Our 2-week washout period was therefore considered adequate to eliminate any carry-over eect from the ®rst to the second treatment period, and therefore formal assessment of carryover eect was not performed.
Categorical variables were described using frequency distributions, and continuous variables were described using the mean and standard deviation (SD).
AUC serum cortisol for the period 08Á00±10Á30 hours was calculated using the trapezoidal rule. Analysis of covariance (ANCOVA) for cross-over trials (29) at the end of each treatment period (Visits 3 and 5) was performed using the appropriate baseline value (Visits 2 and 4, respectively) as the covariate. Variations in period, study centre and treatment were allowed for in the analysis. To remove between-patient variability, a nested eect of patient and sequence was included in the model. Twelvehour urine cortisol excretion was similarly compared. A treatment ratio with corresponding one-sample 95% con®dence interval (95% CI) was calculated as the ratio between AUC serum cortisol after FD and after BUD. All tests for signi®cance were two-tailed, and a P-value of 50Á05 was considered signi®cant. Statistical analysis was conducted using SAS software (SAS Institute, Cany, NC, U.S.A.).
Results
Sixty patients entered the run-in period, of whom 48 met all the eligibility criteria and were randomized to treatment. Forty-®ve patients completed the study. Demographic information is given in Table 1 . The three patients who discontinued treatment all withdrew from the trial because of adverse events while they were receiving BUD (one for pneumonia, one for asthma deterioration, and one because of the medicinal taste of the study treatment).
Before treatment, the mean serum cortisol concentration at 08Á00 hours was 389.5 nmol 1 71 in the BUD group. The corresponding values after treatment were 391Á1 nmol 1 71 and 397Á4 nmol 1 71 respectively. The numbers of patients having serum cortisol values below the normal range were four before treatment with FP and one after treatment with FP. The corresponding numbers before and after treatment with BUD were two and three, respectively. The corresponding numbers for urinary cortisol were 10 and seven for FP, and 11 and 10 for BUD. The eect on mean serum cortisol from 08Á00 to 10Á30 hours was similar for both treatment periods (Fig. 2) . Table 2 shows mean serum cortisol AUC values by treatment sequence and treatment period. Serum cortisol was not in¯uenced by treatment sequence (P0Á23), and there were no statistically signi®cant dierences between FP and BUD (P0Á63) after controlling for baseline values and study centre.
The ratio between the serum cortisol value observed after FP and that observed after BUD was 1Á20 (95% CI 0Á92± 1Á47). Two patients, however, exhibited a very sensitive reaction to BUD but not to FP (serum cortisol AUC of 634Á5 and 739Á0 nmol l 71 after FP, compared with 165Á5 and 97Á8 nmol l 71 after BUD, respectively). Excluding these two patients from the analysis gave a treatment ratio of 0Á99 (95% CI 0Á92±1Á06), clearly indicating that the two drugs had equivalent eects on the HPA axis. Fig. 3 presents serum cortisol AUC at baselines and each treatment period for individual patients. In agreement with the mean data shown in Table 2 , there was no general pattern of suppression by either treatment. The two patients who exhibited high sensitivity to BUD but not FP may be readily identi®ed.
Twelve-hour nocturnal urine cortisol excretion also showed that both treatments had clinically equivalent eects on the HPA axis. Table 3 presents mean nocturnal urinary cortisol excretion by treatment sequence and treatment group. There was no statistically signi®cant dierence between FP and BUD (P0Á80) after controlling for baseline values and study centre, and urine cortisol was not in¯uenced by treatment sequence (P0Á30).
Individual patient data for urine cortisol by treatment period con®rm the above ®nding.
Both FP and BUD were well tolerated. A total of 20 patients reported 29 adverse events, of which the majority occurred in the run-in and washout phases (Table 4) .
Two patients experienced exacerbations of asthma while receiving BUD treatment, compared to none during FP treatment. The other three adverse events which occurred during BUD treatment were abdominal pains, medicinal taste and pneumonia. Medicinal taste was considered almost certainly' to be related to the study treatment but the other events were considered to be unrelated to the study treatment. Both the adverse events which occurred on FP treatment (one patient had mild tonsilitis, and one cut o part of a toe) were considered unrelated to the study medication.
In run-in, the following adverse events were reported: three common cold, one each of erysipelas, gastroenteritis, bursitis of knee, hardening inside lower lip, lumbago, mandibular osteitis and in¯uenza.
In the wash-out period, the adverse events reported were: three common cold, and one each of pruritis of vulva, increased coughing, trauma on left foot, fever, cough, low back pain, thoracic pain, headache, rupture of muscle.
Discussion
This study found that FP 1500 mg day 71 via the Diskus TM dry powder device and BUD 1600 mg day 71 via the Turbuhaler TM were equivalent in their eects on the HPA axis in patients with moderate to severe asthma. Neither treatment produced signi®cant suppression of morning serum cortisol or 12-h nocturnal urine cortisol.
These ®ndings are in agreement with previous studies in patients with moderate to severe asthma. A 12-month study comparing 1500 mg day 71 FP and an equal dose of BDP found that there were no dierences in morning plasma cortisol, urinary free cortisol or response to adrenocorticoptrophic hormone, and neither treatment showed any evidence of plasma cortisol suppression (24) . A shorter, 6-week study in patients with chronic severe asthma compared FP (1000 mg day 71 or 2000 mg day
71
) with BUD (1600 mg day) 71 (25) . Neither FP 1000 mg day 71 nor 1600 mg day 71 suppressed mean plasma cortisol below baseline levels, and although A study in healthy volunteers has claimed that FP has a greater eect on the HPA axis than budesonide. A 4-day repeat-dose study compared BUD (200 mg, 400 mg and 1000 mg twice daily) with FP (200 mg, 375 mg and 1000 mg twice daily) and reported that 24-h pooled plasma cortisol levels were signi®cantly lower during FP than BUD treatment at all dose levels (28) . This was also shown in a cross-over study with 12 mild asthmatics using high doses of FP and BUD inhaled via a MDI (35). These results are at variance with the results of much larger and longer-term clinical studies in asthmatic patients (24, 25) , and the relevance of studies in healthy volunteers to patients with moderate to severe asthma has been questioned (1) .
There is some evidence that patients with asthma and healthy volunteers may dier in their handling of FP. Repeat-dose pharmacokinetic studies of 500 mg FP given twice daily found that plasma FP concentrations at steady state in healthy volunteers were twice as high as those in patients with asthma (31, 32). It appears that healthy volunteers absorb more of an inhaled corticosteroid dose from the lung than asthmatic patients, possibly because of dierences in airway patency (33). This raises further doubts over the validity of healthy volunteer studies as a method of assessing the probable systemic side-eects of inhaled corticosteroids.
This study could be criticized in that the patients were already being treated with high doses of inhaled steroids, and that this could already have had an eect on the HPAaxis. However, very few patients had values below normal levels, and their disease was not progressing while they were under treatment. Our aim was to investigate the eect on the HPA-axis as a primary endpoint in patients who require these high doses. It would have been inappropriate to select patients on low doses or even steroid-naive patients for the study in order to treat them with high doses which they clinically did not require. The rationale for performing a short-term cross-over study was to let the patients be their own controls.
It may also be put forward that this study does not provide any new information in addition to that from previously performed studies. As the devices used in previous mentioned studies are mostly MDIs, we felt that it was important to investigate the eect on the HPA-axis using dry powder devices such as the Diskus TM and Turbuhaler TM , as these are the most commonly used inhalation devices in clinical practice in Scandinavia today.
A meta-analysis of 14 clinical studies has reported that FP is at least as eective as twice the microgram dose of BUD and BDP, over the dose range of 200±1000 mg day 71 FP (30), and more eective in equal doses (24, 25) . Recently, it has been reported that FP 1500 mg day 71 has a greater oral steroid-sparing eect than BUD 1600 mg day 71 in chronic severe asthma (34). Taking this evidence of greater ecacy at equal doses in conjunction with the present study's con®rmation of equivalent systemic activity at almost equal doses in asthmatic patients, it appears that FP may have a better therapeutic ratio than BUD. FP oers the potential for improved disease control in patients 
